Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1456 participants.
Also called NCT06347133
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,456 participants
- Sponsor
- Registry
-
NCT06347133 -
2023-509302-30
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Poland, Slovakia, South Africa, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06347133. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-21 (actual); primary completion 2026-06-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
- Acronym
- MUIR-3
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Plozasiran Injection
- Intervention (Drug)
- Placebo
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct06347133- Content hash
f17970da6a08e21d2382884caccac98971cf3c6db95a1e10e32b5694d9f2945b